Short answer
Protagonist Therapeutics, Inc (PTGX) filed an 8-K current report with the SEC on June 18, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 5.07 (Submission of Matters to a Vote of Security Holders). Stockholders approved the 2026 Equity Incentive Plan, replacing the 2016 Plan.
Protagonist Therapeutics, Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Stockholders approved the 2026 Equity Incentive Plan, replacing the 2016 Plan
- Plan adds 650,000 new shares plus recycling of certain unused or forfeited 2016 Plan awards
- Eligible awards include options, stock appreciation rights, restricted stock, restricted stock units, and performance awards
- Increased equity capacity supports employee retention but creates potential future shareholder dilution
Item 5.07 · Submission of Matters to a Vote of Security Holders
- Two Class I directors, Dinesh V. Patel and Lewis T. Williams, elected through 2029
- Executive compensation approved on advisory basis, with 53,412,559 votes for
- Ernst & Young ratified as independent auditor for fiscal year ending December 31, 2026
- 2026 Equity Incentive Plan approved, supporting future equity-based compensation
- No other matters submitted for shareholder action
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Protagonist Therapeutics, Inc 8-K filings
Get the next PTGX 8-K as it lands
Follow PTGX for push alerts, or ask the research agent what this filing means.